Cancer & SURVIVEiT News

Category Filter:

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma

June 2, 2020

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with…

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma

June 2, 2020

FDA approves daratumumab and hyaluronidase-fihj for multiple myeloma On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with…

FDA approves isatuximab-irfc for multiple myeloma

March 30, 2020

FDA approves isatuximab-irfc for multiple myeloma On March 2, 2020, the Food and Drug Administration approved isatuximab-irfc(SARCLISA, sanofi-aventis U.S. LLC) in combination with pomalidomide and dexamethasone for adult patients with…

Life After Multiple Myeloma: A Survivor Story

March 27, 2020

Although considered relatively uncommon, the American Cancer Society predicts that just over 32,000 new cases of multiple myeloma will be diagnosed in 2020. It can be hard to detect early…

FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant

June 28, 2019

FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with…